MEREO BIOPHARMA GROUP PL-ADR (MREO) Fundamental Analysis & Valuation

NASDAQ:MREO • US5894921072

0.3978 USD
-0.01 (-2.98%)
Last: Mar 5, 2026, 02:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MREO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MREO. MREO was compared to 520 industry peers in the Biotechnology industry. The financial health of MREO is average, but there are quite some concerns on its profitability. MREO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. MREO Profitability Analysis

1.1 Basic Checks

  • In the past year MREO has reported negative net income.
  • MREO had a negative operating cash flow in the past year.
  • MREO had negative earnings in 4 of the past 5 years.
  • MREO had a negative operating cash flow in each of the past 5 years.
MREO Yearly Net Income VS EBIT VS OCF VS FCFMREO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -77.77%, MREO is doing worse than 65.96% of the companies in the same industry.
  • MREO has a Return On Equity (-89.46%) which is in line with its industry peers.
Industry RankSector Rank
ROA -77.77%
ROE -89.46%
ROIC N/A
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MREO Yearly ROA, ROE, ROICMREO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

  • MREO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MREO Yearly Profit, Operating, Gross MarginsMREO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MREO Health Analysis

2.1 Basic Checks

  • MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MREO has been increased compared to 1 year ago.
  • MREO has more shares outstanding than it did 5 years ago.
  • MREO has a worse debt/assets ratio than last year.
MREO Yearly Shares OutstandingMREO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
MREO Yearly Total Debt VS Total AssetsMREO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -9.08, we must say that MREO is in the distress zone and has some risk of bankruptcy.
  • MREO has a Altman-Z score of -9.08. This is in the lower half of the industry: MREO underperforms 71.15% of its industry peers.
  • There is no outstanding debt for MREO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.08
ROIC/WACCN/A
WACC9.03%
MREO Yearly LT Debt VS Equity VS FCFMREO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • MREO has a Current Ratio of 8.71. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.
  • MREO has a Current ratio of 8.71. This is in the better half of the industry: MREO outperforms 76.35% of its industry peers.
  • MREO has a Quick Ratio of 8.71. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.
  • MREO has a Quick ratio of 8.71. This is in the better half of the industry: MREO outperforms 76.35% of its industry peers.
Industry RankSector Rank
Current Ratio 8.71
Quick Ratio 8.71
MREO Yearly Current Assets VS Current LiabilitesMREO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MREO Growth Analysis

3.1 Past

  • MREO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.56%, which is quite impressive.
  • The Revenue for MREO has decreased by -95.00% in the past year. This is quite bad
EPS 1Y (TTM)36.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)-95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 4.03% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.75%
EPS Next 2Y19.32%
EPS Next 3Y9.37%
EPS Next 5Y4.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MREO Yearly Revenue VS EstimatesMREO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MREO Yearly EPS VS EstimatesMREO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2031 2032 2033 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. MREO Valuation Analysis

4.1 Price/Earnings Ratio

  • MREO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MREO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MREO Price Earnings VS Forward Price EarningsMREO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MREO Per share dataMREO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.32%
EPS Next 3Y9.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MREO Dividend Analysis

5.1 Amount

  • No dividends for MREO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MREO Fundamentals: All Metrics, Ratios and Statistics

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (3/5/2026, 2:07:35 PM)

0.3978

-0.01 (-2.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-23
Inst Owners64.06%
Inst Owner Change-36.82%
Ins Owners0.86%
Ins Owner Change0%
Market Cap63.30M
Revenue(TTM)500.00K
Net Income(TTM)-41.69M
Analysts82.86
Price Target1.79 (349.97%)
Short Float %47.51%
Short Ratio0.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-219.99%
Min EPS beat(2)-499.63%
Max EPS beat(2)59.64%
EPS beat(4)1
Avg EPS beat(4)-481.7%
Min EPS beat(4)-1246.69%
Max EPS beat(4)59.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16%
PT rev (3m)-75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-221.5%
EPS NY rev (1m)0%
EPS NY rev (3m)5.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-98.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 126.61
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.77%
ROE -89.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.39%
Cap/Sales 64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.71
Quick Ratio 8.71
Altman-Z -9.08
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)35.04%
Cap/Depr(5y)37.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
EPS Next Y-3.75%
EPS Next 2Y19.32%
EPS Next 3Y9.37%
EPS Next 5Y4.03%
Revenue 1Y (TTM)-95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.13%
EBIT Next 3Y30.55%
EBIT Next 5YN/A
FCF growth 1Y-55.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.38%
OCF growth 3YN/A
OCF growth 5YN/A

MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ

What is the ChartMill fundamental rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MREO.


Can you provide the valuation status for MEREO BIOPHARMA GROUP PL-ADR?

ChartMill assigns a valuation rating of 0 / 10 to MEREO BIOPHARMA GROUP PL-ADR (MREO). This can be considered as Overvalued.


Can you provide the profitability details for MEREO BIOPHARMA GROUP PL-ADR?

MEREO BIOPHARMA GROUP PL-ADR (MREO) has a profitability rating of 0 / 10.


What is the financial health of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

The financial health rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) is 6 / 10.